Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine.
Here we present the case of a 30-year-old woman with type I diabetes mellitus, preeclampsia and treatment resistant persistent hyperemesis gravidarum in her 25th week of gestation who was successfully treated with the antidepressant mirtazapine (Remergil). Nausea and vomiting resolved within 5 days. After discharge from the hospital in 28 weeks of gestation and discontinuation of the medication on her own initiative a relapse occurred, once again with good response to mirtazapine. The drug was continued until birth. At 34 + 0 weeks a cesarean section was performed due to fetal growth restriction and deteriorating preeclampsia. During the second and fourth day postnatal age the child temporarily developed hyperarousal which could be explained by mirtazapine withdrawal.
Schwarzer
V
V
Department of Obstetrics and Prenatal Medicine, University Clinics of Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany.
Heep
A
A
Gembruch
U
U
Rohde
A
A
D000328:Adult; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006939:Hyperemesis Gravidarum / Q000188:drug therapy*; D007231:Infant, Newborn; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000078785:Mirtazapine; D011225:Pre-Eclampsia; D011247:Pregnancy; D012120:Respiration Disorders / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D013610:Tachycardia / Q000139:chemically induced; D014202:Tremor / Q000139:chemically induced
D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D000078785:Mirtazapine